➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

ALDARA Drug Profile

Email this page to a colleague

« Back to Dashboard

When do Aldara patents expire, and what generic alternatives are available?

Aldara is a drug marketed by Bausch and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in ALDARA is imiquimod. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the imiquimod profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aldara

A generic version of ALDARA was approved as imiquimod by FOUGERA PHARMS on February 25th, 2010.

  Get Started Free

Summary for ALDARA
Drug patent expirations by year for ALDARA
Drug Prices for ALDARA

See drug prices for ALDARA

Recent Clinical Trials for ALDARA

Identify potential brand extensions & 505(b)(2) entrants

Columbia UniversityEarly Phase 1
Charite University, Berlin, GermanyPhase 1
Roche Pharma AGPhase 1

See all ALDARA clinical trials

Paragraph IV (Patent) Challenges for ALDARA
Tradename Dosage Ingredient NDA Submissiondate
ALDARA CREAM;TOPICAL imiquimod 020723 2006-10-17

US Patents and Regulatory Information for ALDARA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch ALDARA imiquimod CREAM;TOPICAL 020723-001 Feb 27, 1997 AB RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ALDARA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0145340 99C0005 Belgium   Get Started Free PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
0145340 SPC/GB99/003 United Kingdom   Get Started Free PRODUCT NAME: IMIQUIMOD; REGISTERED: UK EU/1/98/080/001 19980918
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.